OOIR: Observatory of International Research

Papers

(The H4-Index of Nature Reviews Neurology is 59. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?	1209
Technology of deep brain stimulation: current status and future directions	327
Protein transmission in neurodegenerative disease	323
Lifting the mask on neurological manifestations of COVID-19	308
Recovery from disorders of consciousness: mechanisms, prognosis and emerging therapies	262
Applications of machine learning to diagnosis and treatment of neurodegenerative diseases	249
Parkinson disease and the immune system — associations, mechanisms and therapeutics	247
Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities	245
Discovery and validation of biomarkers to aid the development of safe and effective pain therapeutics: challenges and opportunities	217
Maternal immune activation and neuroinflammation in human neurodevelopmental disorders	214
Applications of focused ultrasound in the brain: from thermoablation to drug delivery	200
Blood GFAP as an emerging biomarker in brain and spinal cord disorders	194
Diagnosis and management of migraine in ten steps	183
Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease	166
Prodromal Parkinson disease subtypes — key to understanding heterogeneity	166
Multilevel omics for the discovery of biomarkers and therapeutic targets for stroke	163
Peripheral and central immune system crosstalk in Alzheimer disease — a research prospectus	160
Complement in neurological disorders and emerging complement-targeted therapeutics	154
Improving clinical trial outcomes in amyotrophic lateral sclerosis	146
Cycles in epilepsy	140
Developing the ATX(N) classification for use across the Alzheimer disease continuum	137
Neurological infection with SARS-CoV-2 — the story so far	130
The effects of the COVID-19 pandemic on people with dementia	130
GAD antibodies in neurological disorders — insights and challenges	127
The polygenic architecture of schizophrenia — rethinking pathogenesis and nosology	118

An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders	115
B cells in multiple sclerosis — from targeted depletion to immune reconstitution therapies	108
Post-traumatic stress disorder: clinical and translational neuroscience from cells to circuits	104
Advances in local therapy for glioblastoma — taking the fight to the tumour	102
Inflammation in acquired hydrocephalus: pathogenic mechanisms and therapeutic targets	102
Treatment and management of cognitive dysfunction in patients with multiple sclerosis	100
Management of brain metastases according to molecular subtypes	100
The human connectome in Alzheimer disease — relationship to biomarkers and genetics	98
Virtual reality in research and rehabilitation of gait and balance in Parkinson disease	97
Drug repositioning and repurposing for Alzheimer disease	96
Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours	95
Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility	94
The microbiome–gut–brain axis in Parkinson disease — from basic research to the clinic	93
Stroke in Africa: profile, progress, prospects and priorities	92
Do infections have a role in the pathogenesis of Alzheimer disease?	91
MicroRNAs as regulators of brain function and targets for treatment of epilepsy	89
Circadian rhythms in neurodegenerative disorders	87
Metagenomics for neurological infections — expanding our imagination	86
CRISPR-based functional genomics for neurological disease	86
Hypomyelinating leukodystrophies — unravelling myelin biology	82
Synaptic degeneration in Alzheimer disease	81
Status of peripheral sodium channel blockers for non-addictive pain treatment	79
Spinal muscular atrophy — insights and challenges in the treatment era	79
Non-neuronal cells in amyotrophic lateral sclerosis — from pathogenesis to biomarkers	75
The neuroanatomical–functional paradox in spinal cord injury	74
Development of disease-modifying drugs for frontotemporal dementia spectrum disorders	71
The inter-relationship between delirium and dementia: the importance of delirium prevention	69
Apparent changes in the epidemiology and severity of multiple sclerosis	69
The metabolic basis of epilepsy	67
The importance of ongoing international surveillance for Creutzfeldt–Jakob disease	66
Aducanumab and the FDA — where are we now?	66
Can we learn lessons from the FDA’s approval of aducanumab?	64
The case for low-level BACE1 inhibition for the prevention of Alzheimer disease	63
Lung innervation in the eye of a cytokine storm: neuroimmune interactions and COVID-19	60
White matter injury in infants with intraventricular haemorrhage: mechanisms and therapies	59
Pharmacological brain cytoprotection in acute ischaemic stroke — renewed hope in the reperfusion era	59